Ask about this productRelated genes to: ABL2 antibody
- Gene:
- ABL2 NIH gene
- Name:
- ABL proto-oncogene 2, non-receptor tyrosine kinase
- Previous symbol:
- ABLL
- Synonyms:
- ARG
- Chromosome:
- 1q25.2
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2016-04-25
Related products to: ABL2 antibody
Related articles to: ABL2 antibody
- Protein kinases dysregulation is implicated in various cancer-related processes; however, its clinical utility and biological significance in head and neck squamous cell carcinoma (HNSCC) remain incompletely understood. This study aimed to establish a novel prognostic signature using kinase-related genes (KRGs) for prognostic and therapeutic prediction in HNSCC. - Source: PubMed
Publication date: 2026/05/05
Zhang YangLv PinCao GuangruiQi NaYu MiaoWu Yaping - rearrangements represent a subtype of acute lymphoblastic leukaemia (ALL) associated with poor prognosis and survival. This study reports a high-risk T-cell ALL (T-ALL) case with a novel TPR::ABL2 gene fusion resulting from a chromosomal deletion. Overexpression of in Ba/F3 cells promoted cytokine-independent growth, demonstrating its oncogenic nature. Both primary patient and Ba/F3 cells carrying exhibited kinase activation and sensitivity to tyrosine kinase inhibitors (TKIs). This study expands the repertoire of fusions identified in ALL and supports the incorporation of TKIs into T-ALL treatment regimens to improve outcomes for this subtype. - Source: PubMed
Publication date: 2026/03/02
Lagonik EliasPage Elyse CEadie Laura NSchutz Caitlin ERehn Jacqueline AHeatley Susan LMoore Andrew SHealy MuirinWhyte MoragHughes Timothy PYeung David TWhite Deborah L - The nonreceptor Abelson (Abl) tyrosine kinases have been implicated as key drivers of initiation and progression in Parkinson's disease (PD). Risvodetinib, a potent, brain-penetrant, selective inhibitor of the nonreceptor Abl kinases c-Abl1 and c-Abl2/Arg (collectively, c-Abl), was evaluated in a randomized, double-blind, placebo-controlled phase 2a trial ('the 201 Trial') using once-daily 50 mg, 100 mg, 200 mg or placebo in 137 participants with early, untreated PD. The primary end points in safety and tolerability were met, with 95% of enrolled participants completing the 12-week dosing regimen and a 2-week safety follow-up. Both the average number of adverse events per person and the fraction of participants experiencing at least one treatment-emergent adverse event were similar between risvodetinib and placebo treatment groups, indicating that risvodetinib was safe and well tolerated. Although the trial was not powered to measure efficacy, 14 secondary end points evaluated motor and nonmotor features of disease in hierarchical order. The primary hierarchical secondary end point of the Movement Disorder Society revision to the Unified PD Rating Scale sum of Parts II + III did not reach statistical significance. The study findings indicate that risvodetinib is safe and well tolerated. Longer duration trials are needed to evaluate its potential clinical efficacy. ClinicalTrials.gov registration: NCT05424276 . - Source: PubMed
Publication date: 2026/02/20
Werner M HMcGarry AMeyer CMancino EKlint CPellecchia JKieburtz KLevine TBellaire BGibbons CFreeman REllenbogen AKlos KOspina MHauser R AShannon KAsaad HPark AMcAllister PIsaacson S HLeDoux M SDhall RShpiner DCharles PAgarwal PPeckham EMazzeo PDavis MPahwa RBrodsky MLew MPurino LMantri SParashos SJustiz WChachar MRobottom BBudman EBlindauer KBellows SGoudreau JSteen SOlanow C W - Patients with high-risk neuroblastoma preferentially present with widespread metastasis and often relapse despite intensive therapy, which is the major cause of death of patients with this cancer. Consequently, identifying the molecular drivers of neuroblastoma metastasis holds significant clinical importance. - Source: PubMed
Publication date: 2026/01/12
Gao MingyouCao FangLi JunlingZhang JunXia YurenTian XiangdongLi JieWang DaoweiLu LinGuo YanLiu YuanyuanZhao QiangLiu Yun - - Source: PubMed
Publication date: 2026/01/06
Zhang LiChen YeshengDai YiheMou WeichengDeng PanJin YanXu JingJin Yun